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Abstract: Alveolar bone loss as a result of periodontitis and physiological alveolar bone 
resorption following tooth extraction can be treated and minimized with clinical procedures such 
as periodontal regeneration and socket preservation. The use concentrated growth factor (CGF) 
has received an attention nowadays in clinical practice as source of growth factors. Meanwhile, 
poly lactic-co-glycolic acid (PLGA) microspheres is well known for its use in drug delivery due 
to its high porosity and interconnected pores. The objective of this review paper is to provide an 
overview on the current use of CGF and PLGA in periodontal regeneration in order to promote 
and obtain new bone formation and periodontal attachment. 
1. Introduction 
Conventional open flap debridement is a common 
practice in previous years in treating periodontal 
defect such as intrabony defect and furcation defect. 
With the evolution of knowledge and technologies, 
many surgical techniques and new materials have 
been introduced in order to provide better care for 
the patient and treatment outcome.  These include 
the use of concentrated growth factor (CGF) and 
poly lactic-co-glycolic acid (PLGA).  
 CGF is the third-generation of platelet 
concentrate, containing more growth factors and 
harden fibrin structure as compared to first and 
second generation of platelet concentrate, which 
are platelet-rich plasma (PRP) and platelet rich 
fibrin (PRF) respectively. It is very much useful in 
periodontal and oral surgeries. Meanwhile, a wide 
range of PLGA based drug delivery systems have 
been reported for the treatment or diagnosis of 
various diseases and disorders. Therefore, a 
combination of CGF and PLGA is seen as a novel 
approach to induce bone regeneration and 
connective tissue attachment. Therefore, this 
review article aimed to provide a glance on the 
current use of CGF and PLGA in periodontal 
regeneration in order to promote and obtain new 
bone formation and periodontal attachment.  
2. Concentrated growth factor 
The invention of platelet concentrate provides an 
alternative effective measure to recombinant 
human growth factors to deliver high concentration 
of growth factors to the respected sites. 
Recombinant human growth factors are expensive, 
tend to suffer from instability and quick dilution 
due to solubility of the delivery vehicle. This will 
significantly reduce the half-life of the growth 
factors [1]. Therefore, the use of platelet concentrate 
may overcome those limitations of human 
recombinant growth factors.  
2.1 Platelet concentrate generations 
Nowadays, the use of patient’s own blood that are 
rich in growth factors has gained an attention to 
facilitate the success of periodontal regeneration 
procedure as it is more cost saving as patient’s own 
blood is drawn for its fabrication and thus 
minimizing the risk of cross contamination. The 
discovery of platelet concentrate using autologous 
source of blood started with the development of 
PRP followed by PRF in 2001. 
 CGF is the current generation of platelet 
concentrate product which was first introduced by 
Sacco in 2006 [2], [3]. CGF is produced using single 
centrifugation with alternate speed and this allows 
for isolation of larger and denser fibrin matrix 
compared to PRP and PRF that are rich in growth 
factors. It also results in clot with increase stability, 
strength and protection against plasmin degradation. 
Therefore, it can prolong the release of growth 
factors and action [4]. Following centrifugation, 
three layers were obtained in the vacutainers; 
which are red blood cell layer at the bottom, fibrin 
gel with platelets and growth factor at the middle 
and upper serum layer [5].  
 Various growth factors have been 
identified in the CGF. These include the platelet 
derived growth factor (PDGF)-AB, transforming 
growth factor (TGF), insulin-like growth factor 
Volume 1 | 2019   PROCEEDING BOOK OF
 9TH DENTAL STUDENTS’ SCIENTIFIC SYMPOSIUM 
54 
 
(IGF) -1, bone morphogenetic protein (BMP) -2 
and vascular endothelial growth factor (VEGF). 
Borsani and colleagues observed that PDGF-AB 
and TGF- ß1 had constant release from the CGF 
throughout eight days of experimental period. 
Meanwhile, BMP-2 and VEGF had maximum 
accumulation by day eight and IGF-1 by day 6 [2]. 
Significant amount of concentrations of TGF-ß1, 
PDGF-BB and VEGF also had been observed by 
Masuki and colleagues. They concluded that CGF 
act as a reservoir for various growth factors 
required for healing [6].  
2.2 CGF in periodontal management 
The application of CGF may provide a constant 
supply of growth factors to further enhance healing. 
Bone stromal cells and osteoblast cells that have 
been treated with CGF also showed significant 
higher cell differentiation and proliferation [3], [7]. 
Similarly, application of CGF into human 
periosteal cells resulted in significant cell 
proliferation [6]. This shows that CGF provides a 
medium to augment better periodontal regeneration.  
In the current practice, CGF has been 
fabricated to be used as a membrane in periodontal 
regeneration procedure. Many clinical studies have 
been conducted in order to investigate on the 
effectiveness of CGF in regenerative procedure. 
One of them was done by Qiao and colleagues 
where they used CGF on management of grade II 
furcation involvement. Significant improvement in 
periodontal clinical parameter was noted one year 
after surgery in a group of patients receiving bone 
graft with CGF [8].  
Qiao and colleagues also had conducted a 
study on management of intrabony defect. A 
significant result was also noted in clinical 
parameter and hard tissue fill on radiograph in 
group treated with bovine porous bone mineral and 
CGF [9]. Significant gain in gingival thickness and 
keratinized gingival width on  Miller class I and II 
recession was also noted with utilization of CGF 
combined with coronally advanced flap [10]. These 
in total show that application of CGF may provide 
better treatment outcome on hard and soft tissue 
regeneration.  
3. Poly Lactic-co-Glycolic Acid 
3.1 Properties of PLGA 
PLGA is a copolymer of lactic acid and glycolic 
acid that is FDA-approved biodegradable polymer 
and safe to be used in living cells as it has great 
strength property and highly biocompatible [11].  It 
is a synthetic polymer that can be dissolved by a 
wide range of common solvents. It is a flexible 
material as it can be can be processed into any 
shape and size to encapsulate various agents such 
as drugs, vaccines, proteins and growth factors. 
Molecular weight of the monomers initial, ratio of 
lactic acid and glycolic acid, exposure time to 
water and storage temperature are among several 
factors that influenced the physical properties of 
PLGA [12]. It undergoes degradation by hydrolysis 
and the rate of degradation is also influenced by 
several factors such as the molecular weight, 
composition of lactic and glycolic acid and 
surrounding pH environment [11], [12]. 
3.2 PLGA and periodontitis 
Current approach already focused on the use of 
PLGA in periodontal treatment, particularly used as 
barrier materials in guided tissue regeneration 
(GTR) procedures as the materials are being 
incorporated into the membrane. Yoshimoto and 
colleagues have constructed bilayer PLGA 
membrane and it was found that the use of bilayer 
PLGA membrane successfully inhibited connective 
and epithelial tissue invasion while promoting bone 
regeneration [13]. Besides that, PLGA also were 
constructed as a scaffold to be put into extraction 
sockets and better extraction bone socket 
preservation noted [13]–[15]. Apart from that, PLGA 
has also been incorporated into sutures due to its 
biocompatibility [16]. 
Local delivery of antimicrobials is one of 
the management in treating periodontal defect. 
PLGA microspheres have been fabricated as a 
carrier for doxycycline placed in the periodontal 
pockets in chronic periodontitis patients as an 
adjunct to non-surgical periodontal therapy and was 
observed to provide a sustained release of 
doxycycline up to twenty days after placement [17]. 
The usage of PLGA as scaffold for phenytoin, 
nifedipine and cyclosporine delivery in treating 
periodontal defect have also been investigated 
using Sprague-Dawley rats. It was found that 
PLGA loaded phenytoin resulted in significant new 
alveolar bone formation compared to other drugs 
and the control group [18]. These shows that the use 
of PLGA aids in enhancing the clinical outcome. 
4. Conclusion  
The application of CGF and PLGA have shown 
better clinical outcome in regenerative medicine 
and dentistry. This shows that both materials can 
serve as an alternative to current available materials 
that may further augment clinical outcome and has 
the potential to facilitate better periodontal 
regeneration. 
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